Discover open access scientific publications

Search, annotate, share and cite publications

Publications by T. Jax

New Insulin Glargine 300 Units{middle Dot}mL-1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units{middle Dot}mL-1

Diabetes Care

English

Related publications

When Basal Insulin Is Not Enough: A Dose Response Relationship Between Insulin Glargine 100 Units/mL (U100) and Glycemic Control

Diabetes, Obesity and Metabolism

English

Pdb86 - Cost-Utility Analysis of Insulin Glargine 300 U/Ml Versus Insulin Glargine 100 U/Ml and Insulin Degludec 100 U/Ml in Patients With Type 2 Diabetes Mellitus in Bulgaria

English

Pdb79 - Cost-Utility Analysis of Insulin Glargine 300 U/Ml Versus Insulin Glargine 100 U/Ml and Insulin Degludec 100 U/Ml in Patients With Type 2 Diabetes Mellitus in Croatia

English

In Silico Head-To-Head Comparison of Insulin Glargine 300 U/Ml and Insulin Degludec 100 U/Ml in Type 1 Diabetes

Diabetes Technology and Therapeutics

Medicine

Endocrinology

Medical Laboratory Technology

Metabolism

Diabetes

2020

English

Continuous Glucose Monitoring During Basal–Bolus Therapy Using Insulin Glargine 300 U mL−1 and Glargine 100 U mL−1 in Japanese People With Type 1 Diabetes Mellitus: A Crossover Pilot Study

English

A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study

English

Glycaemic Control, Hypoglycaemia, and Weight Change With Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Japanese Adults With Type 2 Diabetes: A 12-Month Comparison by Concomitant Sulphonylurea and/or Glinide Use

Diabetes, Obesity and Metabolism

English

Comparable Glycaemic Control and Hypoglycaemia in Adults With Type 2 Diabetes After Initiating Insulin Glargine 300 Units/mL or Insulin Degludec: DELIVER Naïve D Real‐world Study

Diabetes, Obesity and Metabolism

English

Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U-300 and Glargine U-100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by T. Jax

New Insulin Glargine 300 Units{middle Dot}mL-1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units{middle Dot}mL-1

Related publications

When Basal Insulin Is Not Enough: A Dose Response Relationship Between Insulin Glargine 100 Units/mL (U100) and Glycemic Control

Pdb86 - Cost-Utility Analysis of Insulin Glargine 300 U/Ml Versus Insulin Glargine 100 U/Ml and Insulin Degludec 100 U/Ml in Patients With Type 2 Diabetes Mellitus in Bulgaria

Pdb79 - Cost-Utility Analysis of Insulin Glargine 300 U/Ml Versus Insulin Glargine 100 U/Ml and Insulin Degludec 100 U/Ml in Patients With Type 2 Diabetes Mellitus in Croatia

In Silico Head-To-Head Comparison of Insulin Glargine 300 U/Ml and Insulin Degludec 100 U/Ml in Type 1 Diabetes

Continuous Glucose Monitoring During Basal–Bolus Therapy Using Insulin Glargine 300 U mL−1 and Glargine 100 U mL−1 in Japanese People With Type 1 Diabetes Mellitus: A Crossover Pilot Study

A Randomized Controlled Trial Comparing Efficacy and Safety of Insulin Glargine 300 Units/mL Versus 100 Units/mL in Older People With Type 2 Diabetes: Results From the SENIOR Study

Glycaemic Control, Hypoglycaemia, and Weight Change With Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in Japanese Adults With Type 2 Diabetes: A 12-Month Comparison by Concomitant Sulphonylurea and/or Glinide Use

Comparable Glycaemic Control and Hypoglycaemia in Adults With Type 2 Diabetes After Initiating Insulin Glargine 300 Units/mL or Insulin Degludec: DELIVER Naïve D Real‐world Study

Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U-300 and Glargine U-100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes